Novalis LifeSciences led the Series B round, which will fund team expansion and platform commercialisation.
"Our mission as a company is to enable widespread patient access to life saving cell and gene therapies. One of the biggest obstacles to achieving this is cell and gene therapy manufacturing processes that are too expensive, too highly variable and too low throughput. Our team is focused on the urgent need to enhance the ability of cell and gene therapy developers, CDMOs and Academic Medical Centers to deliver these therapies to as many patients as possible as quickly as possible,"
The Series B round was led by Eight Roads with participation from existing investors including Union Square Ventures and Seedcamp.
"We started Juro in order to make legal contracts frictionless and accessible to everyone. Legacy processes using Word, PDFs and email slow things down not only for lawyers but for everyone who handles contracts. In the last 12 months our customers have processed more than 250,000 contracts in Juro, without leaving their browser. This has saved customers millions of hours of time and helped them to agree terms faster than ever. We are delighted to partner with Eight Roads as we scale up."
